In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback